Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 15:833:349-356.
doi: 10.1016/j.ejphar.2018.06.024. Epub 2018 Jun 27.

Substrates and potential therapeutics of ventricular arrhythmias in heart failure

Dongze Zhang  1 , Huiyin Tu  1 , Michael C Wadman  1 , Yu-Long Li  2
Affiliations
Review

Substrates and potential therapeutics of ventricular arrhythmias in heart failure

Dongze Zhang et al. Eur J Pharmacol. .

Abstract

Heart failure (HF) is a clinical syndrome characterized by ventricular contractile dysfunction. About 50% of death in patients with HF are due to fetal ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation. Understanding ventricular arrhythmic substrates and discovering effective antiarrhythmic interventions are extremely important for improving the prognosis of patients with HF and reducing its mortality. In this review, we discussed ventricular arrhythmic substrates and current clinical therapeutics for ventricular arrhythmias in HF. Base on the fact that classic antiarrhythmic drugs have the limited efficacy, side effects, and proarrhythmic potentials, we also updated some therapeutic strategies for the development of potential new antiarrhythmic interventions for patients with HF.

Keywords: Antiarrhythmic drugs; Catheter ablation; Heart failure; Ventricular arrhythmia; Ventricular arrhythmic substrate.

PubMed Disclaimer

Conflict of interest statement

Disclosures

No conflicts of interest are declared by the authors.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ajijola OA, Tung R, Shivkumar K, 2014. Ventricular tachycardia in ischemic heart disease substrates. Indian Heart J. 66, S24–S34. - PMC - PubMed
    1. Akar FG, Rosenbaum DS, 2003. Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure. Circ.Res 93, 638–645. - PubMed
    1. Amiodarone trials Meta-analysis investigators, 1997. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet. 350, 1417–1424. - PubMed
    1. Anderson KP, 2003. Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances. Ann.Noninvasive.Electrocardiol 8, 75–89. - PMC - PubMed
    1. Angelini M, Pezhouman A, Savalli N, Pantazis A, Melkonian A, Weiss JN, Karagueuzian HS, Olcese R, 2016. Roscovitine as the archetypal member of a novel class of antiarrhythmics targeting late ICa,L. Biophys.J 110, 272a.

MeSH terms

Substances